{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:04:13Z","timestamp":1784199853675,"version":"3.55.0"},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["openmicrobiologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOMICROJ"],"published-print":{"date-parts":[[2014,7,11]]},"abstract":"<jats:p>Morbidity due to respiratory syncytial virus (RSV) disease is still high in infants and children worldwide during the first two to five years of life. Certain categories of high-risk infants with increased morbidity and mortality attributed to RSV disease have been identified and are included in national recommendations for prophylaxis with the monoclonal RSV antibody palivizumab. Most guidelines recommend palivizumab for preterm infants born less than or equal to 32 weeks gestational age with or without bronchopulmonary dysplasia, those born between 33 and 35 weeks gestational age with additional risk factors, and infants and children with hemodynamically significant congenital heart disease. Over the last years several rare diseases have been identified demonstrating high morbidity associated with RSV disease, thus, extension of guidelines for the prophylaxis with palivizumab for these patients with rare diseases including children with malignancy, congenital and acquired immune deficiency, Down syndrome, neuromuscular impairment, cystic fibrosis, congenital diaphragmatic hernia and other severe respiratory disease is increasingly discussed.<\/jats:p><jats:p>Efficacy of palivizumab prophylaxis is documented by meta-analysis, and different economic analyses demonstrate cost-effectiveness of palivizumab for the most common indications during the first RSV season.<\/jats:p>","DOI":"10.2174\/1874285801408010071","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T09:38:37Z","timestamp":1407749917000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Respiratory Syncytial Virus Infection in High-risk Infants \u2013 an Update on Palivizumab Prophylaxis"],"prefix":"10.2174","volume":"8","author":[{"given":"Bernhard","family":"Resch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"Nair H","year":"2010","unstructured":"Nair H, Nokes DJ, Gessner BD , et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children a systematic review and meta-analysis. Lancet 2010; 375 : 1545-55.","journal-title":"Lancet"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"e1453","DOI":"10.1542\/peds.2010-0507","volume":"126","author":"Garcia CG","year":"2010","unstructured":"Garcia CG, Bhore R, Soriano-Fallas A , et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126 : e1453-60.","journal-title":"Pediatrics"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21552","volume":"47","author":"Brand HK","year":"2012","unstructured":"Brand HK, de Groot R, Galama JM , et al. Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol 2012; 47 : 393-400.","journal-title":"Pediatr Pulmonol"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/17455111.2.3.265","volume":"2","author":"Resch B","year":"2008","unstructured":"Resch B. Palivizumab for the prophylaxis of respiratory syncytial virus infection. Paed Health 2008; 2 : 265-78.","journal-title":"Paed Health"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/14737167.8.6.529","volume":"8","author":"Resch B","year":"2008","unstructured":"Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008; 8 : 529-38.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.prrv.2012.12.005","volume":"14","author":"Resch B","year":"2013","unstructured":"Resch B, Resch E, M ller W. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatr Respir Rev 2013; 14 : 130-6.","journal-title":"Paediatr Respir Rev"},{"key":"refR7","first-page":"917068","author":"Paes B","year":"2013","unstructured":"Paes B, Mitchell I, Li A, Harimoto T, Lanct t KL. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005,-2012,) compared to other international registries. Clin Dev Immunol 2013 2013; 917068.","journal-title":"Clin Dev Immunol 2013."},{"key":"refR8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/infdis\/jis333","volume":"206","author":"Papenburg J","year":"2012","unstructured":"Papenburg J, Hamelin M , Ouhoummane N , et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis 2012; 206 : 178-89.","journal-title":"J Infect Dis"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s10096-012-1617-7","volume":"31","author":"Paes B","year":"2012","unstructured":"Paes B, Mitchell I, Li A, Lanct t KL. CARESS Investigators.A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 2012; 31 : 2703-11.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","volume":"124","author":"ABID P","year":"2009","unstructured":"ABID P. Committee on Infectious Diseases.From the American Academy of Pediatrics Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124 : 1694-701.","journal-title":"Pediatrics"},{"key":"refR11","author":"Makari D","unstructured":"Makari D, Checchia PA, Devincenzo J. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother 2013 10 [Epub ahead of print]","journal-title":"Hum Vaccin Immunother 2013 10. [Epub ahead of print]."},{"key":"refR12","doi-asserted-by":"crossref","first-page":"e59161","DOI":"10.1371\/journal.pone.0059161","volume":"8","author":"Blanken MO","year":"2013","unstructured":"Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L. Dutch RSV Neonatal Network.Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants a multicenter birth cohort study. PLoS One 2013; 8 : e59161.","journal-title":"PLoS One"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/01.inf.0000246978.58565.b5","volume":"25","author":"Doering G","year":"2006","unstructured":"Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age. Pediatr Infect Dis J 2006; 25 : 1188-90.","journal-title":"Pediatr Infect Dis J"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-9-78","volume":"9","author":"Sim es EA Carbonell-Estrany","year":"2008","unstructured":"Sim es EA Carbonell-Estrany, X. Fullarton Jr, et al. European RSV Risk Factor Study Group.. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestationa age based on data from the Spanish FLIP Study. Respir Res 2008; 9 : 78.","journal-title":"Respir Res"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1185\/03007990902929112","volume":"25","author":"Paes B","year":"2009","unstructured":"Paes B, Steele S, Janes M, Pinelli J. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009; 25 : 1585-91.","journal-title":"Curr Med Res Opin"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1524-4733.2009.00586.x","volume":"13","author":"Krilov LR","year":"2010","unstructured":"Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 2010; 13 : 77-86.","journal-title":"Value Health"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2431-12-81","volume":"12","author":"DiFranza Jr","year":"2012","unstructured":"DiFranza Jr, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr 2012; 12 : 81.","journal-title":"BMC Pediatr."},{"key":"refR18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31829061e8","volume":"32","author":"R gnier SA","year":"2013","unstructured":"R gnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae systematic review and meta-analysis. Pediatr Infect Dis J 2013; 32 : 820-6.","journal-title":"Pediatr Infect Dis J"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","volume":"368","author":"Blanken MO","year":"2013","unstructured":"Blanken MO, Rovers MM, Molenaar JM , et al. Dutch RSV Neonatal Network.Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368 : 1791-9.","journal-title":"N Engl J Med"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/HCO.0b013e32835dce2f","volume":"28","author":"Resch B","year":"2013","unstructured":"Resch B, Michel-Behnke I. Respiratory syncytial virus infections in infants and children with congenital heart disease update on the evidence of prevention with palivizumab. Curr Opin Cardiol 2013; 28 : 85-91.","journal-title":"Curr Opin Cardiol"},{"key":"refR21","author":"Chemaly RF","unstructured":"Chemaly RF, Ghantoji SS, Shah DP , et al. Respiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol 2013 Dec 10 [Epub ahead of print]","journal-title":"J Pediatr Hematol Oncol 2013 Dec 10. [Epub ahead of print]."},{"key":"refR22","first-page":"CD007743","volume":"6","author":"Robinson KA","year":"2013","unstructured":"Robinson KA, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2013; 6 : CD007743.","journal-title":"Cochrane Database Syst Rev."},{"key":"refR23","author":"S nchez-Solis M","unstructured":"S nchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients?. A meta-analysis Allergol Immunopathol (Madr) 2013 Nov 11 [Epub ahead of print]","journal-title":"A meta-analysis. Allergol Immunopathol (Madr) 2013 Nov 11. [Epub ahead of print]."},{"key":"refR24","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1542\/peds.2007-0788","volume":"120","author":"Bloemers BL","year":"2007","unstructured":"Bloemers BL, van Furth AM, Weijerman ME , et al. Down syndrome a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. Pediatrics 2007; 120 : e1076-81.","journal-title":"Pediatrics"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.micinf.2010.05.007","volume":"12","author":"Bloemers BL","year":"2010","unstructured":"Bloemers BL, Broers CJ, Bont L, Weijerman ME, Gemke RJ, van Furth AM. Increased risk of respiratory tract infections in children with Down syndrome the consequence of an altered immune system. Microbes Infect 2010; 12 : 799-808.","journal-title":"Microbes Infect"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/INF.0000000000000019","volume":"33","author":"Paes B","year":"2014","unstructured":"Paes B, Mitchell I, Yi H, Li A, Lanct t KL. CARESS Investigators.Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J 2014; 33 : e29-33.","journal-title":"Pediatr Infect Dis J"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1874285801105010155","volume":"5","author":"Simon A","year":"2011","unstructured":"Simon A, Prusseit J, M ller A. Respiratory syncytial virus infection in children with neuromuscular impairment. Open Microbiol J 2011; 5 : 155-8.","journal-title":"Open Microbiol J"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.prrv.2009.06.003","volume":"10","author":"Resch B","year":"2009","unstructured":"Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009; 10 : 148-53.","journal-title":"Paediatr Respir Rev"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1526-0542(09)70010-7","volume":"10","author":"Fauroux B","year":"2009","unstructured":"Fauroux B. Special populations. Paediatr Respir Rev 2009; 10 (Suppl 1 ) : 21-.","journal-title":"Paediatr Respir Rev."},{"key":"refR30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/INF.0b013e31829dff4d","volume":"32","author":"Asner S","year":"2013","unstructured":"Asner S, Stephens D, Pedulla P, Richardson SE, Robinson J, Allen U. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J 2013; 32 : 1073-6.","journal-title":"Pediatr Infect Dis J"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0378-3782(12)70012-9","volume":"88","author":"Manzoni P","year":"2012","unstructured":"Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders a dilemma of specific prevention. Early Hum Dev 2012; 88 (Suppl 2 ) : S34-41.","journal-title":"Early Hum Dev"},{"key":"refR32","author":"Gaboli M","unstructured":"Gaboli M, de la Cruz OA, de Ag ero MI, Moreno-Gald A, P rez GP, de Querol MS. Use of palivizumab in infants and young children with severe respiratory disease a delphi study. Pediatr Pulmonol 2013 Jun 18 doi 101002\/ppul22826 [Epub ahead of print]","journal-title":"Pediatr Pulmonol 2013 Jun 18. doi 10.1002\/ppul.22826 [Epub ahead of print]."},{"key":"refR33","first-page":"CD006602","volume":"4","author":"Andabaka T","year":"2013","unstructured":"Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, BacicVrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013; 4 : CD006602.","journal-title":"Cochrane Database Syst Rev"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta15050","volume":"15","author":"Wang D","year":"2011","unstructured":"Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011; 15 : iii-iv, 1-124.","journal-title":"Health Technol Assess."},{"key":"refR35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3111\/13696998.2012.690013","volume":"15","author":"Mahadevia PJ","year":"2012","unstructured":"Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States a national policy perspective. J Med Econ 2012; 15 : 987-6.","journal-title":"J Med Econ"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3111\/13696998.2012.672942","volume":"15","author":"Weiner LB","year":"2012","unstructured":"Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ 2012; 15 : 997-1018.","journal-title":"J Med Econ"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0b013e318235455b","volume":"31","author":"Resch B","year":"2012","unstructured":"Resch B, Sommer C, Nuijten MJ , et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 2012; 31 : e1-8.","journal-title":"Pediatr Infect Dis J."},{"key":"refR38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","year":"1998","unstructured":"The Impact-RSV Study Group. Paliviumab a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 : 531-7.","journal-title":"Pediatrics"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/jp.2008.28","volume":"28","author":"Frogel M","year":"2008","unstructured":"Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Palivizumab Outcomes Registry Group.Prevention of hospitalization due to respiratory syncytial virus results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28 : 511-7.","journal-title":"J Perinatol"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"Feltes TF","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC , et al. Cardiac Synagis Study Group.Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143 : 532-40.","journal-title":"J Pediatr"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00246-007-9039-5","volume":"29","author":"Cohen SA","year":"2000 2008","unstructured":"Cohen SA, Zanni R, Cohen A, Harrington M, VanVeldhuisen P, Boron ML. Palivizumab Outcomes Registry Group.Palivizumab use in subjects with congenital heart disease results from the 2004, Palivizumab Outcomes Registry. Pediatr Cardiol 2000 2008; 29 : 382-7.","journal-title":"Pediatr Cardiol"}],"container-title":["The Open Microbiology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openmicrobiologyjournal.com\/contents\/volumes\/V8\/TOMICROJ-8-71\/TOMICROJ-8-71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openmicrobiologyjournal.com\/contents\/volumes\/V8\/TOMICROJ-8-71\/TOMICROJ-8-71.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openmicrobiologyjournal.com\/contents\/volumes\/V8\/TOMICROJ-8-71\/TOMICROJ-8-71.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T03:53:30Z","timestamp":1649908410000},"score":1,"resource":{"primary":{"URL":"https:\/\/openmicrobiologyjournal.com\/VOLUME\/8\/PAGE\/71\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7,11]]}},"alternative-id":["TOMICROJ-8-71"],"URL":"https:\/\/doi.org\/10.2174\/1874285801408010071","relation":{},"ISSN":["1874-2858"],"issn-type":[{"value":"1874-2858","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2014-3-7","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-5-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-5-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-7-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}